Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT

User menu

Search

  • Advanced search
eNeuro
eNeuro

Advanced Search

 

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT
PreviousNext
Research ArticleNew Research, Disorders of the Nervous System

Targeted Interneuron Ablation in the Mouse Hippocampus Can Cause Spontaneous Recurrent Seizures

Jay Spampanato and F. Edward Dudek
eNeuro 12 July 2017, 4 (4) ENEURO.0130-17.2017; https://doi.org/10.1523/ENEURO.0130-17.2017
Jay Spampanato
Department of Neurosurgery, University of Utah School of Medicine, Salt Lake City, UT 84108
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jay Spampanato
F. Edward Dudek
Department of Neurosurgery, University of Utah School of Medicine, Salt Lake City, UT 84108
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for F. Edward Dudek
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Movies
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Time line of the experimental protocols. A, For immunohistochemical analysis of the efficacy of DT-induced interneuron ablation, mice were transfected with virus on day 0, followed by DT treatment on days 14 and 15. Six days after the first DT injection, mice were perfused and tissue was harvested and processed for antibody labeling of GFP and GAD67. In a separate set of experiments, virus expression was confirmed at day 14 after transfection. B, To determine the functional result of interneuron ablation, a similar timeline was followed with the exception that on day 0, three littermates were transfected with virus and then on each of the days 6-8, one of those three mice was used for ex vivo slice recordings. This experiment was repeated at least three times with the animal treatment condition (experimental or controls) rotated through days 6-8. This series of experiments was also conducted with ex vivo recordings performed on days 2-4. C, To determine the effect of interneuron ablation on whole brain function in vivo, mice were implanted with a wireless transmitter at the time of virus transfection (day 0 of the experiment and day 14 relative to DT treatment). A 14-d baseline LFP was recorded before induction of ablation, followed by continuous LFP recording.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    AAV-DTR transfection and expression in the CA1 subregion of the hippocampus. A, Expression of DTR-EGFP can be seen by immunohistochemical labeling with anti-EGFP antibody at two weeks posttransfection. The transfected area extends throughout the medial-lateral expanse of the CA1 region of the hippocampus. Arrows indicate the pyramidal cell body layer of CA1. B, C, Higher power images demonstrate cell-specific expression in the oriens and pyramidal cell layers. D, E, Putative synaptic densities can be seen as puncta in the bright fluorescent band of the SLM region, as well as puncta in the pyramidal cell layer surrounding putative principal cell bodies (asterisks). F-H, Representative images from serial sections from one mouse demonstrate the area of transfection of the dorsal-medial region of CA1. Some expression can be seen in the deep cortical layers. Images were taken from sections corresponding to bregma -1.34 (F), -2.18 (G), and -2.80 (H). The injection was targeted to bregma -1.85.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Hippocampal interneurons are lost after targeted ablation by systemic DT administration. A-C, EGFP-expressing interneurons in the CA1 region coexpress GAD67 (arrows). D-F, At 6 d after DT treatment, a significant loss of EGFP-expressing (green, D) and GAD67-expressing (red, E) cells can be seen in the merged image (F), across all subregions of CA1. G. Quantification of the average number of virus-transfected cells (n = 3 mice/group) demonstrated a large population of EGFP-expressing cells in virus-transfected control mice that had not been given DT, and a significant reduction in EGFP-expressing cells in virus-transfected mice that had been given DT. H, Quantification of GAD67-expressing cells (in the same tissue as G for virus-transfected control and virus-transfected ablated) confirmed that the ablation resulted in a significant reduction of interneurons across all regions in the ablated (n = 3) compared to the control mice (grouped for comparison, n = 6: n = 3 virus-transfected control and n = 3 toxin control). Asterisks indicate significance at p < 0.01, two-way ANOVA, control versus ablated.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Interneuron ablation results in a specific reduction in the frequency of mIPSCs. Whole-cell recordings from CA1 pyramidal cells demonstrated that the mice that underwent the ablation procedure (DTR + DT) had a reduction in the frequency of mIPSCs. Data are arranged so that the start of each successive line is a continuation of the line above it, and the mIPSCs can be seen as sharp upward deflections from baseline.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Quantification of the properties of the mIPSCs and mEPSCs. A, The interevent interval, amplitude and decay time of both mIPSCs and mEPSCs recorded in each cell are plotted for saline-transfected controls treated with DT (saline + DT, blue), virus-transfected controls treated with saline (DTR + saline, green) and interneuron-ablated mice transfected with virus and treated with DT (DTR + DT, red). Symbols indicate data from individual cells, and bars indicate the group averages. Data are plotted for the time point of days 6-8 after DT treatment. At this time, CA1 pyramidal cells from the experimental mice had a specific deficit in the frequency of mIPSCs (asterisks, p < 0.01, ANOVA; Tables 1, 2) but not the amplitude or decay time, consistent with the loss of inhibitory synapses. B, The >10-fold shift in interevent interval of mIPSCs can also be seen as a large shift in the cumulative probability plot for the DTR + DT compared to controls.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Targeted interneuron ablation produces seizures. A, Example of a seizure recorded in the dorsal CA1 region of the hippocampus using a miniature wireless telemetry recording device mounted to the animal’s head with an electrode positioned near the CA1 pyramidal cell layer. B, Expansion of the boxed regions of the recording in A demonstrating the changes in the recorded waveforms during the seizure (1 and 2), the postictal depression (3), and return to normal baseline activity (4).

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Interneuron ablation produces both convulsive and nonconvulsive seizures. Nonconvulsive and convulsive seizures were indistinguishable in the LFP recordings. The top and bottom seizures occurred ∼8 min apart in the same mouse. The first seizure (top) was associated with behavioral arrest and a gentle head nod side-to-side. The second seizure (bottom) was convulsive with forelimb clonus. Boxed regions are expanded below for both seizures to illustrate the similarities in waveforms during both high-frequency and large-amplitude periods of activity.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8.

    SRSs after interneuron ablation generally occur during a limited time period. A, Daily seizure activity is plotted for two weeks of baseline recording beginning with virus transfection and transmitter implantation. This was followed by continuous recording through the DT treatment period (shown to start at day 0, and lasting for 2 d, red bar) and beyond for several weeks for each mouse. SRSs were seen primarily in the first week after ablation. E20057 had nine seizures spanning from day 3 to day 8; four were confirmed to be convulsive (level 3 or higher). E20061 had three convulsive seizures (two level 3 and one level 5) on days 3-4. E20062 had a total of six seizures over a time period of ∼9 h. Seizures began just before the start of day 6 (11:33 P.M. on day 5); two were convulsive (level 4), four were nonconvulsive (level 2). E20064 had a total of 41 seizures that began on day 5; the first nine seizures were nonconvulsive (level 2), they then progressed to convulsive seizures (level 3-5). 42-5 had 10 seizures on day 4 to day 6; eight were confirmed nonconvulsive (level 2). 42-44 had two seizures on day 3; video from this day was either corrupt or missing. B, Interseizure interval is plotted for all seizure intervals ≤24 h for all mice. The histogram demonstrates that seizures were not confined to brief intervals, thus demonstrating that the interneuron-ablation treatment did not produce a discreet period of SE. C, The histogram of seizure durations illustrates that SRSs induced by interneuron ablation typically had a duration of 30-65 s.

  • Figure 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 9.

    Comparison of the time course of seizures with synaptic pathophysiology. Seizure frequency (i.e., number of seizures per day, right axis) for all mice is plotted (vertical bars) in reference to the fold change in interevent intervals (IEIs, horizontal bars, left axis) of the mIPSCs (red) and mEPSCs (black) recorded from pyramidal cells, in separate cohorts of mice, during the time periods of days 2-4 and days 6-8 after DT treatment. Fold change in IEI was calculated as the ratio of ablated to control so that an increase in fold change indicates a longer interval between events (and therefore lower frequency) in the ablated mice. The occurrence of SRSs is concurrent with the decrease in mIPSC frequency (i.e., the increase in mIPSC IEI). The fold change in IEI of the mEPSCs remains close to 1 at both time periods, demonstrating no concomitant change in excitatory synapses on to pyramidal cells over these time periods.

Tables

  • Figures
  • Movies
    • View popup
    Table 1.

    Synaptic and intrinsic properties of CA1 pyramidal cells at 2-4 d after ablation. Values are given as average (Ave) ± standard deviation (SD).

    AAV-DTR + DTAAV-DTR aloneDT aloneStatistics
    Ave ± SDAve ± SDAve ± SDOne-Way ANOVA
    mEPSCIEI (ms)1524.9 ± 933.9890.0 ± 455.21306.5 ± 312.6F(2,20) = 1.76, p = 0.20
    Amplitude (pA)22.9 ± 2.921.0 ± 1.120.1 ± 3.9F(2,20) = 2.05, p = 0.16
    Decay (ms)4.7 ± 0.95.0 ± 0.95.3 ± 1.7F(2,20) = 0.40, p = 0.67
    n (mice/cells)3/83/73/5
    mIPSCIEI (ms)181.6 ± 154.4148.2 ± 64.1124.8 ± 46.0F(2,22) = 0.59, p = 0.56
    Amplitude (pA)35.1 ± 4.638.0 ± 5.433.5 ± 6.2F(2,22) = 1.36, p = 0.28
    Decay (ms)7.5 ± 1.17.5 ± 1.46.9 ± 1.4F(2,22) = 0.39, p = 0.68
    n (mice/cells)3/83/83/7
    Intrinsic propertiesWhole-cell capacitance (pF)27.8 ± 5.929.9 ± 7.127.1 ± 5.6F(2,22) = 0.41, p = 0.67
    Input resistance (MΩ)126 ± 33129 ± 20136 ± 39F(2,22) = 0.18, p = 0.84
    Membrane time constant (τw, ms)2.2 ± 0.52.2 ± 0.42.1 ± 0.4F(2,22) = 0.12, p = 0.89
    • View popup
    Table 2.

    Synaptic and intrinsic properties of CA1 pyramidal cells at 6-8 d after ablation

    AAV-DTR + DTAAV-DTR aloneDT aloneStatistics
    Ave ± SDAve ± SDAve ± SDOne-way ANOVA
    mEPSCIEI (ms)1806.8 ± 805.92465.6 ± 1091.52199.4 ± 1057.2F(2,44) = 1.75, p = 0.19
    Amplitude (pA)31.7 ± 4.132.8 ± 5.931.0 ± 7.4F(2,44) = 0.36, p = 0.70
    Decay (ms)3.3 ± 0.4#3.7 ± 0.64.5 ± 1.3F(2,44) = 7.05, p < 0.01
    n (mice/cells)4/164/154/14
    mIPSCIEI (ms)3129.0 ± 3391.5*378.7 ± 433.3120.5 ± 45.7F(2,44) = 10.3, p < 0.01
    Amplitude (pA)40.1 ± 8.143.1 ± 7.335.8 ± 6.2F(2,44) = 3.67, p = 0.64
    Decay (ms)6.8 ± 1.56.3 ± 0.86.3 ± 0.9F(2,44) = 1.15, p = 0.33
    n (mice/cells)4/164/154/14
    Intrinsic propertiesWhole-cell capacitance (pF)33.6 ± 6.130.4 ± 6.730.6 ± 6.9F(2,44) = 1.15, p = 0.33
    Input resistance (MΩ)148 ± 68115 ± 38100 ± 37F(2,44) = 3.61, p = 0.04
    Membrane time constant (τw, ms)1.9 ± 0.62.1 ± 0.62.5 ± 0.8F(2,44) = 2.55, p = 0.09
    • ↵* Significant difference between AAV-DTR + DT and both AAV-DTR alone and DT alone (one-way ANOVA, Tukey’s multiple comparison test).

    • #Significant difference between AAV-DTR + DT and DT alone (one-way ANOVA, Tukey’s multiple comparison test).

    • View popup
    Table 3.

    Seizure properties

    Animal IDSeizure duration (s)Number of seizuresInterseizure interval (h:m:s)
    Ave ± SDAve ± SDShortestLongest
    E2005738 ± 5922:54:26 ± 31:03:270:19:3592:53:34
    E2006129 ± 1233:15:28 ± 3:54:220:29:456:01:12
    E2006243 ± 361:53:15 ± 2:17:100:07:0353:15:20
    E2006448 ± 124119:04:33 ± 28:29:360:11:29119:55:47
    42-561 ± 11108:12:56 ± 6:25:332:05:2519:48:37
    42-4442 ± 8749:51:07 ± 112:08:172:49:04278:44:41
    42-44*38 ± 625:13:44 ± N/A5:13:445:13:44
    • ↵* Seizures after the ablation procedure only.

Movies

  • Figures
  • Tables
  • Movie 1.

    Nonconvulsive seizure with behavioral pause associated with “looking back and forth” (at 54 s).

  • Movie 2.

    Convulsive seizure with a period of forelimb clonus.

  • Movie 3.

    Convulsive seizure with forelimb clonus and/or head twitching accompanied by rearing.

Back to top

In this issue

eneuro: 4 (4)
eNeuro
Vol. 4, Issue 4
July/August 2017
  • Table of Contents
  • Index by author
Email

Thank you for sharing this eNeuro article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Targeted Interneuron Ablation in the Mouse Hippocampus Can Cause Spontaneous Recurrent Seizures
(Your Name) has forwarded a page to you from eNeuro
(Your Name) thought you would be interested in this article in eNeuro.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Targeted Interneuron Ablation in the Mouse Hippocampus Can Cause Spontaneous Recurrent Seizures
Jay Spampanato, F. Edward Dudek
eNeuro 12 July 2017, 4 (4) ENEURO.0130-17.2017; DOI: 10.1523/ENEURO.0130-17.2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Targeted Interneuron Ablation in the Mouse Hippocampus Can Cause Spontaneous Recurrent Seizures
Jay Spampanato, F. Edward Dudek
eNeuro 12 July 2017, 4 (4) ENEURO.0130-17.2017; DOI: 10.1523/ENEURO.0130-17.2017
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Significance Statement
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Acknowledgments
    • Footnotes
    • References
    • Synthesis
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • CA1 Ablation
  • epilepsy
  • GABAergic
  • Local Field Potential
  • status epilepticus

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

New Research

  • A Very Fast Time Scale of Human Motor Adaptation: Within Movement Adjustments of Internal Representations during Reaching
  • Optogenetic Activation of β-Endorphin Terminals in the Medial Preoptic Nucleus Regulates Female Sexual Receptivity
  • Hsc70 Ameliorates the Vesicle Recycling Defects Caused by Excess α-Synuclein at Synapses
Show more New Research

Disorders of the Nervous System

  • The PDGFBB-PDGFRβ Pathway and Laminins in Pericytes Are Involved in the Temporal Change of AQP4 Polarity during Temporal Lobe Epilepsy Pathogenesis
  • The Ventral Pallidum Innervates a Distinct Subset of Midbrain Dopamine Neurons
  • Rethinking Alzheimer's: Harnessing Cannabidiol to Modulate IDO and cGAS Pathways for Neuroinflammation Control
Show more Disorders of the Nervous System

Subjects

  • Disorders of the Nervous System
  • Home
  • Alerts
  • Follow SFN on BlueSky
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Latest Articles
  • Issue Archive
  • Blog
  • Browse by Topic

Information

  • For Authors
  • For the Media

About

  • About the Journal
  • Editorial Board
  • Privacy Notice
  • Contact
  • Feedback
(eNeuro logo)
(SfN logo)

Copyright © 2025 by the Society for Neuroscience.
eNeuro eISSN: 2373-2822

The ideas and opinions expressed in eNeuro do not necessarily reflect those of SfN or the eNeuro Editorial Board. Publication of an advertisement or other product mention in eNeuro should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in eNeuro.